On Friday, Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) opened lower -8.67% from the last session, before settling in for the closing price of $257.91. Price fluctuations for ALNY have ranged from $141.98 to $304.39 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 97.61% annually for the last half of the decade. Company’s average yearly earnings per share was noted 43.95% at the time writing. With a float of $127.97 million, this company’s outstanding shares have now reached $128.98 million.
In an organization with 2100 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 85.37%, operating margin of -8.98%, and the pretax margin is -15.33%.
Alnylam Pharmaceuticals Inc (ALNY) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Alnylam Pharmaceuticals Inc is 0.90%, while institutional ownership is 96.58%. The most recent insider transaction that took place on Aug 20 ’24, was worth 4,200,000. In this transaction Chief Executive Officer of this company sold 15,000 shares at a rate of $280.00, taking the stock ownership to the 73,441 shares. Before that another transaction happened on Aug 20 ’24, when Company’s Officer proposed sale 15,000 for $280.00, making the entire transaction worth $4,200,000.
Alnylam Pharmaceuticals Inc (ALNY) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.77 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.77) by -0. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.53 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 43.95% per share during the next fiscal year.
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) Trading Performance Indicators
Check out the current performance indicators for Alnylam Pharmaceuticals Inc (ALNY). In the past quarter, the stock posted a quick ratio of 2.69. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 13.25. Likewise, its price to free cash flow for the trailing twelve months is 1727.88.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.62, a number that is poised to hit -0.59 in the next quarter and is forecasted to reach -1.08 in one year’s time.
Technical Analysis of Alnylam Pharmaceuticals Inc (ALNY)
Let’s dig in a bit further. During the last 5-days, its volume was 1.01 million. That was better than the volume of 0.88 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 3.09%. Additionally, its Average True Range was 9.73.
During the past 100 days, Alnylam Pharmaceuticals Inc’s (ALNY) raw stochastic average was set at 6.20%, which indicates a significant increase from 1.28% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 48.64% in the past 14 days, which was higher than the 39.22% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $274.95, while its 200-day Moving Average is $210.51. However, in the short run, Alnylam Pharmaceuticals Inc’s stock first resistance to watch stands at $248.19. Second resistance stands at $260.83. The third major resistance level sits at $267.48. If the price goes on to break the first support level at $228.90, it is likely to go to the next support level at $222.25. Assuming the price breaks the second support level, the third support level stands at $209.61.
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) Key Stats
There are currently 128,981K shares outstanding in the company with a market cap of 27.75 billion. Presently, the company’s annual sales total 1,828 M according to its annual income of -440,240 K. Last quarter, the company’s sales amounted to 500,920 K and its income totaled -111,570 K.
